Baker Avenue Asset Management, LP Provention Bio, Inc. Transaction History

Baker Avenue Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $80,655 - $118,702	-14,250 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $60,719 - $116,700	-6,000 Reduced 29.63%	14,250 $149,000
Q4 2020 Feb 17, 2021	SELL	$11.79 - $18.94 $188,640 - $303,040	-16,000 Reduced 44.14%	20,250 $343,000
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $113,740 - $167,200	-11,000 Reduced 23.28%	36,250 $465,000
Q2 2020 Aug 12, 2020	SELL	$7.81 - $17.0 $175,725 - $382,500	-22,500 Reduced 32.26%	47,250 $667,000
Q1 2020 May 14, 2020	SELL	$5.42 - $17.75 $116,530 - $381,625	-21,500 Reduced 23.56%	69,750 $641,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $532,900 - $1.36 Million	91,250 New	91,250 $1.36 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Baker Avenue Asset Management, LP with notifications on news.